Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

PURPOSE: There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675689/
https://ncbi.nlm.nih.gov/pubmed/22025146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.5040
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados